Cancer Genetics rises on reverse stock split, M&A advisory deal

Interpace Biosciences

25/10/2019 15:46

** Diagnostics company's shares  CGIX.O  up 6% at $3.45, on
track to end a five-day losing streak 
    ** CGIX on Thursday said it hired H.C. Wainwright to
identify a deal involving co, including a potential merger or
acquisition  urn:newsml:reuters.com:*:nGNX5Mn69g
    ** Co also unveiled a 1-for-30 reverse stock split of its
outstanding shares, which comes into effect after markets open
on Friday     
    ** CGIX entered into a settlement agreement with
privately-held NovellusDx with which it had terminated a merger
with co in December 2018 
    ** Co also said it received $6 mln in cash out of the $7.7
mln due from Interpace Diagnostics Group  IDXG.O  as part of the
previously announced sale of CGIX's BioPharma
business urn:newsml:reuters.com:*:nGNXlPf8B
    ** More than 450k shares traded, 2.8x their 50-day moving
avg
    ** Stock down 55.25% this year, as of last close 

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 7786;))